Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers.
Xerient is pursuing the development of novel therapeutics and diagnostic technologies that can dramatically improve the survival of these patients.
Making radiotherapy available for pancreatic cancer patients by introducing protection prior to applying radiation. Radiotherapy has the benefit of locally targeting a tumor and not affecting the entire body.
The early detection of pancreatic, colon, and stomach cancer cells and then reliable follow-up monitoring by our novel diagnostic assays, using our proprietary antibodies to detect newly discovered specific biomarkers.
The pancreas is an organ with functions that are critical to proper digestion and the absorption of nutrients in the body. Its location, adjacent to the intestines, which are highly sensitive to radiation, hinders the use of radiotherapy in treating pancreatic cancer. As no early stage diagnostic is available, the disease is usually discovered at a very late stage.
Survival has not improved substantially over nearly 40 years
55,440 diagnosed with pancreatic cancer in the U.S. alone and 495,000 worldwide
We will advance care for pancreatic cancer to detect it earlier, and with more reliability. We will expand the possibilities for cancer care through a solution that promotes radiotherapy as a real alternative for treatment.
© All rights reserved to Xerient